Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3% on Insider Selling

Spyre Therapeutics, Inc. (NASDAQ:SYRE)’s stock price traded down 6.3% during trading on Friday following insider selling activity. The company traded as low as $69.84 and last traded at $69.7750. 925,243 shares were traded during trading, an increase of 1% from the average session volume of 914,881 shares. The stock had previously closed at $74.45.

Specifically, CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $71.37, for a total transaction of $1,070,550.00. Following the transaction, the chief executive officer owned 612,540 shares in the company, valued at $43,716,979.80. This trade represents a 2.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sheldon Sloan sold 78,333 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $71.50, for a total value of $5,600,809.50. Following the transaction, the insider owned 78,333 shares in the company, valued at approximately $5,600,809.50. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In other Spyre Therapeutics news, CFO Scott L. Burrows sold 12,500 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $71.37, for a total transaction of $892,125.00. Following the transaction, the chief financial officer owned 97,994 shares in the company, valued at $6,993,831.78. This trade represents a 11.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on SYRE shares. Deutsche Bank Aktiengesellschaft raised their price objective on Spyre Therapeutics from $55.00 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Leerink Partners raised their price objective on Spyre Therapeutics from $49.00 to $106.00 and gave the stock an “outperform” rating in a research note on Monday, April 13th. Robert W. Baird raised their price objective on Spyre Therapeutics from $65.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Stifel Nicolaus raised their price objective on Spyre Therapeutics from $70.00 to $92.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Finally, Wedbush raised their price objective on Spyre Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Spyre Therapeutics presently has a consensus rating of “Buy” and an average target price of $85.08.

Spyre Therapeutics News Summary

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Yahoo Finance ran a feature asking whether Spyre is one of the small-cap stocks “on fire,” highlighting recent momentum and investor interest that can support valuation and liquidity. Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
• Neutral Sentiment: Spyre’s Compensation Committee approved inducement stock options totaling 20,800 shares for four non-executive hires — a common hiring tool; dilution is small but notable if hiring accelerates. Spyre Therapeutics Announces Grants of Inducement Awards
• Negative Sentiment: CEO Cameron Turtle sold 15,000 shares at ~$71.37 under a 10b5-1 plan (≈$1.07M); although planned, large insider sales can signal executives taking profits after the run-up. SEC Form 4 — Cameron Turtle
• Negative Sentiment: Insider Sheldon Sloan sold 78,333 shares at ~$71.50 (~$5.6M), reducing his position by half via a 10b5-1 plan — a large, headline-grabbing sale that likely pressured sentiment. SEC Form 4 — Sheldon Sloan
• Negative Sentiment: CFO Scott L. Burrows sold 12,500 shares at ~$71.37 (~$892k) under a 10b5-1 plan, trimming ~11% of his holdings — another insider sale adding to downward pressure. SEC Form 4 — Scott L. Burrows

Spyre Therapeutics Stock Performance

The company has a market cap of $5.47 billion, a price-to-earnings ratio of -33.38 and a beta of 3.12. The company has a fifty day moving average of $51.75 and a two-hundred day moving average of $37.49.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.04). Equities analysts expect that Spyre Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Spyre Therapeutics

Several hedge funds have recently modified their holdings of SYRE. Summit Securities Group LLC acquired a new stake in shares of Spyre Therapeutics during the 1st quarter valued at $28,000. Russell Investments Group Ltd. boosted its holdings in shares of Spyre Therapeutics by 2,881.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after acquiring an additional 4,092 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Spyre Therapeutics during the 4th quarter valued at $74,000. Tower Research Capital LLC TRC boosted its holdings in shares of Spyre Therapeutics by 182.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after acquiring an additional 3,725 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Spyre Therapeutics by 61.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock valued at $124,000 after acquiring an additional 1,435 shares in the last quarter. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.